Categories Earnings, Technology

Autodesk’s shares tank after Q1 results miss expectations

Autodesk Inc. (NASDAQ: ADSK) missed market estimates on both revenue and earnings for the first quarter of 2020, sending shares sliding nearly 9% in after-market hours on Thursday.  

Total revenue of $735 million was up 31% on a reported basis and 30% on a constant currency basis versus last year, but fell short of the consensus estimate of $740 million.   

Autodesk reports first quarter 2020 earnings results

GAAP net loss was $24.2 million, or $0.11 per share, compared to $82.4 million, or $0.38 per share, in the prior-year quarter. Adjusted EPS totaled $0.45, missing the forecast of $0.46.   

Total annualized recurring revenue (ARR) was $2.83 billion, up 33% year-over-year on a reported basis, and 32% on a constant currency basis. Subscription plan ARR totaled $2.38 billion, up 70% as reported and 69% in constant currency. Maintenance plan ARR was $448 million, down 38% as reported and 40% in constant currency. Core ARR increased 29% while cloud ARR jumped 164%.

Total deferred revenue, which is defined as deferred revenue plus unbilled deferred revenue, grew 24% to $2.74 billion on a year-over-year basis. Billings totaled $798 million.

For the second quarter of 2020, Autodesk expects revenue to be $782 million to $792 million. GAAP EPS is expected to be $0.13-0.17 while adjusted EPS is expected to be $0.59-0.63.  

For fiscal-year 2020, revenue is expected to grow 26-28% to $3.25-3.30 billion. GAAP EPS is projected to be $0.83 to $1.02, while non-GAAP EPS is estimated to be $2.71 to $2.90. Total ARR is expected to grow 27-29% to $3.50-3.55 billion while billings are expected to increase 50-53% to $4.05-4.15 billion.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top